针对肥胖来治疗心脏衰竭
1Oxford Centre for Magnetic Resonance Research, University of Oxford Oxford, UK.
European cardiology
|January 12, 2026
概括
肥胖显著导致心力衰竭 (HF). 蓄意减肥干预措施,包括减肥手术和GLP-1激动剂,有望改善肥胖和高血压肺炎患者的心脏健康和结果.
科学领域:
- 心脏病学 心脏病学
- 代谢健康 代谢健康
- 肥胖医学 肥胖医学
背景情况:
- 肥胖是一个全球性的健康危机,越来越多地与心力衰竭 (HF) 发生率和进展有关.
- 肥胖和HF之间的关系是复杂的,受血动力学,代谢和炎症途径的影响.
- "肥胖悖论"在理解已确定的HF和肥胖症患者的预后方面提出了挑战.
研究的目的:
- 审查肥胖和心力衰竭之间的双向关系.
- 总结关于故意减肥对心脏结构,功能和HF患者临床结果的影响的证据.
- 探索各种减肥干预措施在心力衰竭背景下管理肥胖的有效性.
主要方法:
- 文献综述综合了关于肥胖和心力衰竭的当前研究.
- 对减肥手术,饮食干预,药物治疗 (例如GLP-1受体激动剂) 和运动计划研究的证据分析.
- 检查与减肥干预相关的临床结果,心脏结构和功能.
主要成果:
- 腹腔外科手术在不同表型的心力衰竭患者中表现出一致的好处.
- 药理干预,特别是葡萄糖类-1 (GLP-1) 受体激活剂,显示出心脏代谢改善的潜力.
- 结构化的炼和康复计划也显示出在心力衰竭中管理肥胖的新兴益处.
结论:
- 针对肥胖症对于改善高风险心力衰竭人群的发病率和死亡率至关重要.
- 需要进一步的研究来澄清长期干预疗效和GLP-1受体激动剂和SGLT2抑制剂等疗法的综合益处.
- 在不断增长的肥胖流行病背景下,有意减肥策略为控制心力衰竭提供了一个有希望的途径.
相关概念视频
01:22Heart Failure VI: Adjunct Therapies
245
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
245
01:30Heart Failure V: Medical Management
208
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
208
01:30Heart Failure VII: Nursing Interventions
408
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
408
01:22Heart Failure Drugs: β-Blockers
755
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
755
01:17Pathophysiology of Heart Failure
2.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.8K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
909
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
909